Physician profile
Ara Travers
NPI 1659314979
$924.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $130 · 2021: $33.14 · 2022: $12.57 · 2024: $17.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $133.04 | 2019 | |
| Radius Health, INC. | $130.39 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $125.90 | 2019-2024 | Andexxa |
| Glaxosmithkline, LLC. | $95.86 | 2019 | |
| Astellas Pharma US INC | $95.22 | 2019 | |
| Allergan, INC. | $77.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.71 | 2021-2022 | |
| Amarin Pharma, INC. | $45.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.95 | 2019 | |
| Merck Sharp & Dohme LLC | $27.90 | 2019 | |
| Amgen INC. | $27.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.42 | 2019 | |
| Melinta Therapeutics, LLC | $12.01 | 2019 | |
| Lilly USA, LLC | $11.43 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11.26 | 2019 | |
| Pfizer INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ara Travers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.